Viewing nowCombinationNanomet XR Sustained-release Tablets 100/1000 mg
Sitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Hankyung Hutex Pharmaceutical Co., Ltd.

MFDS item code 202201881 · Approved 2022.05.09 · Insurance code 649105540
This product's status changed to Approval withdrawn on 2026.02.10. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improves blood glucose control in patients with type 2 diabetes
This medication is used as an adjunct therapy for patients with type 2 diabetes to aid in blood sugar control by using sitagliptin and metformin together, effectively improving blood sugar management in conjunction with diet and exercise therapy.
In antidiabetic therapy, the dose of this product should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this product should be taken with food once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this product must be swallowed whole and should not be split, crushed, ground, or chewed. The 100/1000 mg extended-release tablet of this product is taken once daily, 1 tablet per dose. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets of this product take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this product is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this product. 2. Patients receiving metformin: The recommended initial dose of this product for patients who cannot achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 100 mg and the patient's current dose of metformin. Patients switching to this product from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. Patients receiving immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this product's 50/1000 mg extended-release tablet once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this product is a total daily dose of sitagliptin 100 mg, and the initial dose of metformin should take the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. The starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should not be initiated with this product. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this product must be discontinued immediately. Patients with hepatic impairment This product should not be administered to patients with hepatic impairment because it contains metformin.
This medication contains both sitagliptin and metformin, which are used to control blood sugar. During treatment, serious allergic reactions may occur rarely, so if symptoms such as rash or difficulty breathing appear, you should stop taking the medication immediately and consult a doctor. This medication can cause pancreatitis (inflammation of the pancreas), so if you have abdominal pain, vomiting, or severe abdominal discomfort, you should inform your healthcare provider immediately. Patients with impaired kidney function, acute infections, or dehydration should not take this medication, and caution is particularly required for patients with moderate to severe kidney impairment. Before and after tests using iodine contrast agents, this medication should be temporarily discontinued, and it should be resumed only after confirming normal kidney function. It is safer for pregnant women or those who may become pregnant, as well as breastfeeding mothers, not to take this medication. This medication may cause hypoglycemia, so do not skip meals and eat regularly, and be especially cautious of hypoglycemia symptoms when taken with other antidiabetic agents. It is important to regularly monitor kidney function, blood tests, and vitamin B12 levels during treatment. Additionally, alcohol should be avoided, as excessive alcohol intake may increase the risk of lactic acidosis while taking this medication. In cases of planned surgery or severe infections, or severe trauma, this medication should be temporarily discontinued and resumed after recovery. Increases in exercise levels or irregular eating patterns may also pose a risk of hypoglycemia, so caution is advised. If unusual symptoms occur while taking this medication, you should consult your doctor immediately, especially if you experience blisters or severe pain on your skin, you should inform your healthcare provider immediately.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to protect it from air and moisture. It is important to maintain the storage temperature between 1 and 30 degrees Celsius. By storing it this way, the efficacy of the medication can be safely maintained.
Light blue oval shaped sustained-release film-coated tablet with a convex shape on both sides
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Hankyung Hutex Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.